EPHA 2018 Universal Access and Affordable Medicines Forum
TRAILBLAZERS
ROUTES TO BETTER AND AFFORDABLE MEDICINES BY 2025
What do we want from our future medicines policy?
20 November 2018 • Scotland House, Brussels
The 2018 Universal Access and Affordable Medicines Forum came at a critical juncture for pharmaceutical policy in Europe.
On 20 November 2018, Trailblazers from all parties involved in the European access to medicines debate gathered to take stock of recent unprecedented political developments and to discuss policy recommendations for the next European Commission and Member States’ priorities in terms of medicines policy.
-
Get updated on major political developments and their relevance for the access to medicines debate
-
Understand where the innovation ecosystem is headed towards
-
Enrich your understanding of public investment in medical R&D in Europe
-
Gain insight into key stakeholders’ upcoming health agendas
Re-live the event
Programme
09:00-09:30
REGISTRATION AND COFFEE
09:30-09:45
WELCOME AND INTRODUCTION
09:45-11:15
ACCESS TO MEDICINES IN EUROPE: ARE PAYERS FACING A DEAD END?
11:15-11:30
COFFEE BREAK
11:30-13:00
THOUGHT LEADERS FORUM: WHERE DO WE STAND AND WHERE IS MEDICINES POLICY IN EUROPE HEADING?
13:00-14:00
LUNCH
14:00-15:30
PUBLIC INVESTMENT IN MEDICAL R&D IN EUROPE: WHY, WHEN, HOW & WHO?
15:30-15:45
COFFEE BREAK
15:45-17:15
THE INNOVATION ECOSYSTEM IN EUROPE: HOW WILL IT LOOK LIKE IN 2025?
17:15-18:00
NETWORKING RECEPTION
Speakers
Yannis Natsis, Policy Manager for Universal Access and Affordable Medicine, European Public Health Alliance (EPHA)
Jo De Cock, CEO, National Institute of Health and Disability Insurance (RIZIV/INAMI), Belgium
Marjan Suselj, General Director, Health Insurance Institute of Slovenia (HIIS)
Evert Jan van Lente, Director EU-Affairs, AOK-Bundesverband, Germany
Adrian van den Hoven, Director General, Medicines For Europe
Paola Testori Coggi, Italian Medicines Agency (AIFA)
Clemens Auer, Special Envoy for Health, Federal Ministry of Labour, Social Affairs, Health and Consumer Protection, Austria
Carlo Maria Marenghi, Legal Attaché for Intellectual Property and Trade issues, Holy See
Ri De Ridder, President, Médecins du Monde, Belgium
Nathalie Moll, Director General, European Federation of Pharmaceutical Industries and Associations, (EFPIA)
Marie-Paule Kieny, Director of Research, French National Institute of Health and Medical Research (INSERM), France
Stefano Vella, Director, National Center for Global Health, Istituto Superiore di Sanita (ISS), Italy
Stuart Pritchard, Manager, European Union and Public Affairs, Wellcome Trust
Viviana Galli, Coordinator, European Alliance for Responsible R&D and Affordable Medicines
Rufus Pollock, Enterpreneur, Founder & President of Open Knowledge
Jan Van den Bossche, Partner, Fund+, Belgium
Zoltán Kaló, Professor of Health Economics, Eötvös Loránd University (ELTE), Hungary
Carin Uyl-de Groot, Professor of Health Technology Assessment, Erasmus School of Health Policy & Management, Erasmus University Rotterdam, Netherlands
Moderator: Tania Dussey-Cavassini
Event gallery
In the press
Follow the discussion on social media
<blockquote class="twitter-tweet" data-lang="en"><p lang="en" dir="ltr">The next European Commission & <a href="https://twitter.com/EU_Health?ref_src=twsrc%5Etfw">@EU_Health</a> should have a clear, robust mandate to prioritise health. DG Sante is there to defend public health policy not to act like a second DG GROW repeating pro-business arguments <a href="https://twitter.com/hashtag/Trailblazers2025?src=hash&ref_src=twsrc%5Etfw">#Trailblazers2025</a> <a href="https://twitter.com/hashtag/access2medicines?src=hash&ref_src=twsrc%5Etfw">#access2medicines</a> <a href="https://t.co/Hw5FYIp22q">pic.twitter.com/Hw5FYIp22q</a></p>— Yannis Natsis (@YNatsis) <a href="https://twitter.com/YNatsis/status/1064804695456313345?ref_src=twsrc%5Etfw">November 20, 2018</a></blockquote><!-- [et_pb_line_break_holder] --><script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script><!-- [et_pb_line_break_holder] -->
<blockquote class="twitter-tweet" data-lang="en"><p lang="en" dir="ltr">Interesting twist in the debate. Q from the floor : How can Europe better incentivize and keep research here? A from two economists (1 private, 1 academia) on the panel: there are more than enough. Incentives already. We are even overshooting. <a href="https://twitter.com/hashtag/trailblazers2025?src=hash&ref_src=twsrc%5Etfw">#trailblazers2025</a> <a href="https://twitter.com/EPHA_EU?ref_src=twsrc%5Etfw">@EPHA_EU</a> <a href="https://t.co/qCVA87a4Y9">pic.twitter.com/qCVA87a4Y9</a></p>— Dimitri Eynikel (@DimitriEynikel) <a href="https://twitter.com/DimitriEynikel/status/1064910780129263617?ref_src=twsrc%5Etfw">November 20, 2018</a></blockquote><!-- [et_pb_line_break_holder] --><script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script><!-- [et_pb_line_break_holder] -->
<blockquote class="twitter-tweet" data-lang="en"><p lang="en" dir="ltr"><a href="https://twitter.com/hashtag/Trailblazers2025?src=hash&ref_src=twsrc%5Etfw">#Trailblazers2025</a> What about a public fund operating like a venture capital with profits reinvested into the fund to support more new start-ups, and with ethical clauses for valorisation which preserves public benefits? Venture capitalist Jan Van den Bossche: it might be feasible <a href="https://t.co/FkGqwA9oGz">pic.twitter.com/FkGqwA9oGz</a></p>— Marie-Paule Kieny (@mpkieny) <a href="https://twitter.com/mpkieny/status/1064907137313374208?ref_src=twsrc%5Etfw">November 20, 2018</a></blockquote><!-- [et_pb_line_break_holder] --><script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script><!-- [et_pb_line_break_holder] -->
<blockquote class="twitter-tweet" data-lang="en"><p lang="en" dir="ltr"><a href="https://twitter.com/EUCouncil?ref_src=twsrc%5Etfw">@EUCouncil</a> <a href="https://twitter.com/Europarl_EN?ref_src=twsrc%5Etfw">@Europarl_EN</a> and <a href="https://twitter.com/EU_Health?ref_src=twsrc%5Etfw">@EU_Health</a> should step up there actions to deal with the high level of frustration of health policy makers with unsustainable pharmaceutical prices, says Clemens Auer at EPHA <a href="https://twitter.com/hashtag/trailblazers2025?src=hash&ref_src=twsrc%5Etfw">#trailblazers2025</a> <a href="https://t.co/eipRhk351u">pic.twitter.com/eipRhk351u</a></p>— AIM (@AIM_Healthcare) <a href="https://twitter.com/AIM_Healthcare/status/1064834389937393664?ref_src=twsrc%5Etfw">November 20, 2018</a></blockquote><!-- [et_pb_line_break_holder] --><script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script>
<blockquote class="twitter-tweet" data-conversation="none" data-lang="en"><p lang="en" dir="ltr">"Attach public interest conditions to research funding, access principles and the inclusion of access plans, which should be public and evaluated throughout." <a href="https://twitter.com/Vivivovi?ref_src=twsrc%5Etfw">@Vivivovi</a> European Alliance for Responsible R&D and Affordable Medicines <a href="https://twitter.com/hashtag/Trailblazers2025?src=hash&ref_src=twsrc%5Etfw">#Trailblazers2025</a> <a href="https://t.co/27vyReXvDT">pic.twitter.com/27vyReXvDT</a></p>— EPHA (@EPHA_EU) <a href="https://twitter.com/EPHA_EU/status/1064881234571132928?ref_src=twsrc%5Etfw">November 20, 2018</a></blockquote><!-- [et_pb_line_break_holder] --><script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script>
Past EPHA Universal Access and Affordable Medicines Fora
Game Changers for better and affordable medicines for Europe
The 2017 Universal Access and Affordable Medicines Forum of the European Public Health Alliance
Under the auspices of the Bulgarian Ministry of Health
Healthy Innovation for all
The 2016 Universal Access and Affordable Medicines Forum of the European Public Health Alliance
Organised under the auspices of the Polish Permanent Representation to the EU
Contact
Yannis Natsis
Policy Manager for Universal Access and Affordable Medicines
